Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
(2016) In Vaccine p.1559-1559- Abstract
- Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing and specific HPV-binding serum antibodies were measured at baseline and 12 months after the first vaccine dose. Presence of neutralizing and binding antibodies had good agreement (average Kappa for HPV types 6, 11, 16, 18, 31, 33 and 45 was 0.65). At baseline, 88% of subjects had antibodies against at least one genital HPV. Following vaccination with Cervarix™, all subjects became seropositive for HPV16 and 18. After Gardasil™ vaccination, 96% of subjects seroconverted for HPV16 and 73% for HPV18. Levels of HPV16-specific antibodies were <1 international unit (IU)... (More)
- Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing and specific HPV-binding serum antibodies were measured at baseline and 12 months after the first vaccine dose. Presence of neutralizing and binding antibodies had good agreement (average Kappa for HPV types 6, 11, 16, 18, 31, 33 and 45 was 0.65). At baseline, 88% of subjects had antibodies against at least one genital HPV. Following vaccination with Cervarix™, all subjects became seropositive for HPV16 and 18. After Gardasil™ vaccination, 96% of subjects seroconverted for HPV16 and 73% for HPV18. Levels of HPV16-specific antibodies were <1 international unit (IU) in 87% of study subjects before vaccination but >10IU in 85% of study subjects after vaccination. Antibodies against non-vaccine HPV types appeared after Gardasil™ vaccination for >50% of vaccinated females for HPV 31, 35 and 73 and for >50% of Cervarix™-vaccinated females for HPV 31, 33, 35, 45, 56 and 58. Cross-reactivity with non-genital HPV types was also detected. In conclusion, HIV-infected subjects responded to HPV vaccination with induction of neutralizing antibodies against both vaccine and non-vaccine types. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8824983
- author
- Faust, Helena ; Toft, Lars ; Sehr, Peter ; Müller, Martin ; Bonde, Jesper ; Forslund, Ola LU ; Østergaard, Lars ; Tolstrup, Martin and Dillner, Joakim
- organization
- publishing date
- 2016-02-16
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Vaccine
- pages
- 1565 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:26896686
- scopus:84960463991
- wos:000372763300009
- pmid:26896686
- ISSN
- 1873-2518
- DOI
- 10.1016/j.vaccine.2016.02.019
- language
- English
- LU publication?
- yes
- id
- 26f248ec-65e0-4014-bd50-ef952e860ba3 (old id 8824983)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26896686?dopt=Abstract
- date added to LUP
- 2016-04-01 09:57:12
- date last changed
- 2024-02-21 00:46:52
@article{26f248ec-65e0-4014-bd50-ef952e860ba3,
abstract = {{Ninety-one HIV-infected individuals (61 men and 30 women) were randomized to vaccination either with quadrivalent (Gardasil™) or bivalent (Cervarix™) HPV vaccine. Neutralizing and specific HPV-binding serum antibodies were measured at baseline and 12 months after the first vaccine dose. Presence of neutralizing and binding antibodies had good agreement (average Kappa for HPV types 6, 11, 16, 18, 31, 33 and 45 was 0.65). At baseline, 88% of subjects had antibodies against at least one genital HPV. Following vaccination with Cervarix™, all subjects became seropositive for HPV16 and 18. After Gardasil™ vaccination, 96% of subjects seroconverted for HPV16 and 73% for HPV18. Levels of HPV16-specific antibodies were <1 international unit (IU) in 87% of study subjects before vaccination but >10IU in 85% of study subjects after vaccination. Antibodies against non-vaccine HPV types appeared after Gardasil™ vaccination for >50% of vaccinated females for HPV 31, 35 and 73 and for >50% of Cervarix™-vaccinated females for HPV 31, 33, 35, 45, 56 and 58. Cross-reactivity with non-genital HPV types was also detected. In conclusion, HIV-infected subjects responded to HPV vaccination with induction of neutralizing antibodies against both vaccine and non-vaccine types.}},
author = {{Faust, Helena and Toft, Lars and Sehr, Peter and Müller, Martin and Bonde, Jesper and Forslund, Ola and Østergaard, Lars and Tolstrup, Martin and Dillner, Joakim}},
issn = {{1873-2518}},
language = {{eng}},
month = {{02}},
pages = {{1559--1559}},
publisher = {{Elsevier}},
series = {{Vaccine}},
title = {{Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.}},
url = {{http://dx.doi.org/10.1016/j.vaccine.2016.02.019}},
doi = {{10.1016/j.vaccine.2016.02.019}},
year = {{2016}},
}